Marie Attard Selected Research

dabrafenib

1/2023	A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
1/2019	Redifferentiation of a BRAFK601E-Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marie Attard Research Topics

Disease

4	Thyroid Neoplasms (Thyroid Cancer) 01/2023 - 01/2019
1	Hypertension (High Blood Pressure) 02/2024
1	Respiratory Insufficiency (Respiratory Failure) 02/2024
1	Pain (Aches) 02/2024
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 02/2024
1	Asthenia 02/2024
1	Hemorrhage 02/2024
1	Paraganglioma (Paragangliomas) 02/2024
1	Neoplasms (Cancer) 01/2023
1	Anaplastic Thyroid Carcinoma 01/2021
1	Hyperthyroidism 01/2019
1	Thyrotoxicosis 01/2019
1	Neoplasm Metastasis (Metastasis) 01/2019

Drug/Important Bio-Agent (IBA)

3	trametinibIBA 01/2023 - 01/2019
3	IodineIBA 01/2023 - 01/2019
2	dabrafenibIBA 01/2023 - 01/2019
1	Sunitinib (Sutent)FDA Link 02/2024
1	lenvatinibIBA 01/2021
1	Thyroglobulin FDA Link 01/2019
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2019
1	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2019
1	Triiodothyronine (Liothyronine)FDA LinkGeneric 01/2019

Therapy/Procedure

2	Thyroidectomy 01/2023 - 05/2021
1	Contraindications 01/2019